Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Assessing pharma headwinds and tailwinds in mid-2021

By Brian Buntz | June 17, 2021

vaccine

[Photo by Frank Meriño from Pexels]

Now that we have passed the year’s midway mark, pharma continues to be in a unique position.

While COVID-19 gave the industry an opportunity for a reputational reset in 2020, the pandemic is now a net positive for the industry, according to the recent Moody’s report, “Solid demand, lift from COVID-19 products continue to drive positive outlook.”

While demand for COVID-19 vaccines has ebbed recently in the U.S., Moody’s projects strong vaccine sales overall for the remainder of 2021. Pfizer (NYSE:PFE) upped their guidance for vaccine sales to $26 billion in their first-quarter earnings report. “Their approach to guidance for revenue is based on contracts that have been signed,” said Michael Levesque, lead author of the report. Thus, any future contracts that Pfizer signs after that guidance update will further expand their guidance for COVID-19 vaccine sales.

Vaccine sales haven’t had a material impact, however, on Johnson & Johnson’s (NYSE:JNJ) bottom line for a few reasons. First, the company has vowed not to profit from the vaccine as long as the pandemic persists. In addition, the vaccine faced a temporary regulatory pause and manufacturing challenges in the U.S. But given their global presence, “they should still see material sales coming in during the year,” Levesque said.

While the pandemic had a varied impact on the pharmaceutical industry, the overall impact in terms of product sales was modest. “I would say it was within just a couple of negative percentage points,” Levesque said. Therapies that required administration in a provider’s office or onsite, however, saw a downturn — “especially in 2Q and 3Q 20.”

AstraZeneca (LON:AZN) still does not have authorization to sell its COVID-19 vaccine in the U.S., but globally, the product has found broad use.

The prospect of drug pricing reform is still a threat

Drug costs

Image by Thomas Breher from Pixabay

It remains difficult to gauge the likelihood of drug pricing reform in the U.S. in the near term, but it remains “a credit risk sector-wide,” Levesque said. The risk is especially acute for companies with a high percentage of sales in the U.S. “But it’s an issue globally in many markets outside the U.S.,” Levesque said.

That said, drug pricing reform in many places outside of the U.S. is often easier to predict. “We already have a good sense of what the reforms look like because they’re pretty steady,” Levesque said. “They lead to things like a mid-single-digit pricing decline in places like Europe, where that’s been the case for many years.” Conversely, some of the drug-pricing reform proposals could have “a very material impact well in excess of the mid-single-digit decline,” according to Levesque.

If no drug pricing reform happens in the relatively near term in the U.S., that doesn’t mean it will subside. “The longer there’s no real change, the more that the pressure will continue to build,” Levesque said.

Cancer, autoimmune disease and rare disease remain ripe for innovation

Cancer

Image by PDPics from Pixabay

The oncology sector has long been one of the pharma area’s bright spots. New drugs introduced in recent decades have had a material impact on cancer mortality. And yet, “even though there has been a lot of innovation and blockbuster immunotherapy drugs, there’s still a need for even more effective treatments that can improve survival for a greater number of patients,” Levesque said

Sponsors are experimenting with various approaches — exploring new indications for existing cancer drugs and testing novel drug combinations. “There’s also more focus on specific mutations that impact certain cancers,” Levesque said. “We’re seeing a lot of investment in drugs that may only be appropriate for 5% or 10% of patients, but the treatment can be quite effective for those patients.”

The penetration of drugs used to treat many autoimmune diseases remains at an early stage. Biologics, for instance, have shown considerable promise in treating psoriasis, but the market penetration of such drugs remains low.

Drug developers also continue to make progress in understanding the genetic underpinnings of rare diseases and developing products targeting them. “Because many rare diseases are so severe — and because they impact children in many cases — some of these drugs can command very high price points,” Levesque said. For that reason, rare disease is an area where the industry is willing to make R&D investments. “There is also potential in gene therapy, which can be a potential treatment for certain rare diseases in that area as well,” Levesque said. “So I think we’ll continue to see investment there.”

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE